Stem markers Nestin, Sox2, and Oct-4 were all reduced with the combination therapy as compared to monotherapy (Hämmerle et al., 2013), exemplifying the importance of differentiation inducers used together with other agents to enhance the anti-CSC effect in the malignant, sub-population of these NB tumors. The gene discussed is SOX2; the disease is neuroblastoma.